Your Cart
Your cart is empty

Looks like you haven't added any test / checkup to your cart

Add Test / Checkup
User Sign In Health checkup offers

IHC - GCDFP15- Test, Price, Normal Range | Sprint Diagnostics Hyderabad

Immunohistochemistry (IHC) is a crucial tool in the field of pathology, used to study the localization of proteins in cells of a tissue section. The GCDFP15 (Gross Cystic Disease Fluid Protein 15) is a particular marker tested for through this method. The expression of GCDFP15 is associated with cells originating from breast tissue, which makes it valuable in the diagnosis and study of breast cancer, specifically, to determine if a cancer of unknown origin has metastasized from the breast.

This marker has been especially useful in distinguishing breast carcinomas from lung carcinomas as well as identifying primary and metastatic apocrine carcinoma. However, it is important to note that not all breast cancers express GCDFP15. Therefore, a negative result does not necessarily exclude breast origin. The marker's role is significant enough to aid in the treatment planning of breast cancer, especially in cases where the cancer has spread to other parts of the body.

  • Test Name: IHC - GCDFP15
  • Sample Type: Tissue
  • Preparations Required: No specific instructions are required for this test.
  • Report Time: 3 days

Home Sample Collection Process

Book your convenient slot
Book your convenient slot
Sample Collection by Phlebotomist
Sample Collection by Phlebotomist
Reporting of the sample at lab
Reporting of the sample at lab
Download Reports
Download Reports
Frequently Asked Questions

The GCDFP15 IHC test is done to detect the presence of breast carcinoma cells in a tissue sample, especially when investigating metastatic cancer of unknown primary origin.

No, fasting is not required for this test.

The sample is usually collected by a healthcare professional during a biopsy procedure where a small piece of tissue is removed for examination.

A positive result suggests the presence of cells expressing GCDFP15, which is usually associated with cells originating from breast tissue. However, it's important to discuss the results with your healthcare provider for a complete interpretation.

The frequency of this test depends on the clinical context and is determined by your healthcare provider.

No specific precautions are required for this test.

Certain factors may influence the test results, including the type and stage of the cancer.

If the test value is abnormal, you should consult an oncologist or a pathologist for further advice and management.

The pain associated with this test is mostly from the biopsy procedure used to collect the tissue sample.

While the test can help identify the presence of certain cancer cells, it does not determine the stage of the cancer. Further tests would be needed for staging.

This test can aid in determining the origin of metastatic cancer when the primary source is unknown.

A negative result does not necessarily exclude breast origin as not all breast cancers express GCDFP15. Always discuss your results with your healthcare provider.

There are no known modifiable factors that can affect GCDFP15 levels as it is related to the presence of certain cancer cells.

Yes, the type and stage of the cancer are non-modifiable factors that can affect the levels of GCDFP15.

There's no specific preparation required for this test. However, you should follow your healthcare provider's instructions regarding the biopsy procedure.

As the sample for this test is usually collected through a biopsy, potential risks are those associated with a biopsy procedure. These might include infection, bleeding, or an allergic reaction to anesthesia. However, these risks are generally low as the procedure is performed under sterile conditions.

A positive result indicates the presence of GCDFP15, generally associated with cells originating from breast tissue. This doesn't establish a definitive diagnosis, but it provides valuable information to your healthcare provider. If you get a positive result, you should discuss with your healthcare provider about the next steps, which might include further testing, imaging, or treatment planning.

A negative result does not necessarily rule out breast cancer as not all breast cancers express GCDFP15. If your result is negative, your healthcare provider will guide you through what the next steps might be, based on your overall clinical picture.

Yes, the IHC-GCDFP15 test can be useful in monitoring the treatment progress in some cases, especially if the initial test was positive. Repeat testing can help determine if the treatment is working by ing a decrease in GCDFP15 expression.

Yes, usually the GCDFP15 IHC test is one part of a comprehensive diagnostic process that may include other tests such as imaging studies, molecular tests, other IHC tests, and sometimes even genetic tests.

Medications do not directly affect the result of the IHC-GCDFP15 test. However, medications that affect the growth and spread of cancer cells could indirectly affect the test results. Always inform your healthcare provider about any medications you are currently taking.

This test is particularly useful for those diagnosed with cancer of unknown primary origin. It's also used when breast cancer is suspected based on other diagnostic tests or clinical examination. However, its suitability and necessity are determined by your healthcare provider based on your specific clinical situation.

Schedule Test in Your Available Time
Locations Near You in Hyderabad
  • 4KM from Madhapur
  • 3KM from Banjara Hills
  • 1.9KM from Yusufguda
  • 3KM from Madhura Nagar
  • 5KM from Shaikpet